President and Chief Executive Officer, Praxis Precision Medicines
Appears in 1 story
Leading company through transition to commercial-stage
Children with SCN2A and SCN8A developmental and epileptic encephalopathies have never had a drug designed for their condition, cycling through four or more unapproved medications as seizures persist and development regresses. The FDA accepted Praxis Precision Medicines' application for relutrigine and granted priority review, with a decision expected by September 27, 2026.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
